EndoAnchors to prevent or fix type I endoleaks: Mid-term results of the Global ANCHOR Registry

Jean-Paul P.M. de Vries, MD, PhD St. Antonius Hospital, Nieuwegein, The Netherlands *On behalf of the ANCHOR Collaborators*



CACVS Paris Jan 2015

Disclosures


Consultant: Aptus Endosystems, Endologix Inc, Medtronic

Research funding: Cardionovum, Vascular Insights

Speakers fee: BTG

Without EndoAnchors, What Are Our Treatment Options?

- * <u>When</u> they can be placed, Cuff/Palmaz do not always work
 - * Greater radial force may not resolve focal issue
 - * Additional components place greater dilating force on a diseased aorta
- * Limited viable options for treating type I endoleak in short necks
 - * Coils/Onyx require precise ID of leak paths, carry nontarget embolization risk
 - * Patient may be unfit for more complex procedures
- * How do we **prevent** further disease progression & complications?
 - * Cuffs, Palmaz, Coils, Onyx cannot resist neck dilatation



What New Capabilities Can We Achieve With EndoAnchors?


* Target and close type I endoleak paths

- * Analogous to an *interrupted suture*
- * Customize placement to anatomy
- * Provide an adjunctive treatment where options can be limited
 - * Such as short, hostile infra-renal necks
- * Augment seal strength without increasing seal area
 - * Potentially avoid more complex procedures or covering vessels



EndoAnchors do not inhibit other adjunctive or future options

>4,000 PATIENTS TREATED, >23,000 ENDOANCHORS IMPLANTED TO-DATE



ANCHOR Registry: A Study of the *Real-World* Usage & Outcomes of the Heli-FX EndoAnchor System




Registry Design	Prospective, observational, international, multi-center, dual-arm
Current	505 patients as of 31 Dec 2014
Enrollment	36 US Sites, 17 European Sites



Treatment Arms	"Primary" – Up to 1000 pts	
	"Revision" – Up to 1000 pts	
Duration	5 Years	
Follow-up	Per Standard of Care at each center & investigator discretion	

Indicated Reasons for EndoAnchoring in ANCHOR: Complications and Concerns for Failure



- 48.6% → prophylaxis (n=235)
- 51.4% → treatment (n=249): Acute + Late Type Ia Endoleaks, Migration +/- Endoleak


Median # EndoAnchors Implanted				
Primary Arm: 6				
Revision Arm:	7			
Combined:	7			

Majority Proximal Necks in ANCHOR are <u>Hostile</u> per Corelab

Proximal Neck Anatomical Characteristics	Primary N = 237	Revision N = 92	
Max Aneurysm Diameter [mean]	56 mm	69 mm	
Neck Length [mean]	17 mm	14 mm	
Neck Length ≤10mm	88/237 (37.1%)	45/92 (48.9%)	
Necks Length ≤15mm	127/237 (53.6%)	60/92 (65.2%)	
Neck Diameter [mean]	26 mm	30 mm	
Conical Neck (10% increase over 10mm)	36.7%	48.9%	
Neck Thrombus [mean thickness over circumference]	0.7 mm	1.0 mm	
Neck Calcium [mean thickness over circumference]	1.2 mm	0.3 mm	
Hostile Neck*	91.6%	84.8%	

*Hostile neck defined by neck diameter >28mm, length <10mm, angulation >60°, thrombus or calcium over >180 degrees of circumference

All Major Endografts Have Required EndoAnchors to Treat Complications and Address Concerns



Primary Arm n=361 (75%)

Revision Arm n=123 (25%)

Talent 16%

20%

Excluder 20%


Low Proximal Seal-Related Events in Midterm Follow-Up *Despite Hostile Neck Anatomy*

	Primary		Revision	
	Mean ± SD	Min - Max	Mean ± SD	Min - Max
Length of clinical follow-up	14.9± 7.7 months	0.0 - 33.2 months	15.0 ± 7.9 months	1 - 32.0 months
Rupture post-repair	0/361 (0.0%)		0/123 (0.0%)	
Aneurysm-related reinterventions	16/361 (4.4%)		21/123 (17.1%)	
Proximal-seal related re-interventions ¹	3/361 (0.8%)		10/123* (8.1%)	
Aneurysm-related deaths	4/361** (1.1%)		0/123 (0.0%)	

¹Includes total re-interventions for type Ia endoleaks, type III endoleaks and graft migrations *10 patients with 16 re-interventions. 2 patients with multiple revisions: 1 with 4, another with 2 **Site reported cause of death: left sided ischemic bowel, respiratory failure, MOF

High Success Treating Type Ia Complications Despite Hostile Neck Anatomy

Freedom from Type Ia Endoleak at Final Angio by complication type



Based on Corelab,


99.3% of proximal necks meet criteria for hostile*

*Hostile necks are based on CT images available for Corelab analysis and presence of type Ia endoleaks are based on site reported angio results.

Defined by neck diameter >28mm, length <10mm, angulation >60°, thrombus or calcium over >180 degrees of circumference

Low Proximal Seal Re-Interventions in F/U Despite Hostile Neck Anatomy

Freedom from Type 1a Endoleak Related Re-interventions, by type of complication treated



Mean follow-up (CT-scans): 15 ± 8 months

Recent Published Article in JVS: As Prophylaxis, Strong Outcomes in ANCHOR

From the Society for Vascular Surgery

Analysis of EndoAnchors for endovascular aneurysm repair by indications for use

Jean-Paul P. M. de Vries, MD,^a Kenneth Ouriel, MD,^b Manish Mehta, MD, MPH,^c David Varnagy, MD,^d William M. Moore Jr, MD,^c Frank R. Arko, MD,^c James Joye, DO,^a and William D. Jordan Jr, MD,^b Nieuwgein, The Netherlands; New York and Albany, NT; Orlando, Ha; Lexington, SC; Charlotte, NC; Mountain View, Calif; and Birmingham, Ala

Objective: The proximal aortic neck remains one of the challenges of endovascular aneurysm repair (EVAR), and the risk of type Ia endoleak and endograft migration is increased in patients with short, large-diameter, or highly angulated necks. EndoAnchors have been used as an adjunct to EVAR in such patients, and the aim of this study was to assess their benefit analyzed by indication for use.

Methode During a 2-year period, 319 patients were enrolled at 43 sites in the Ancuryam Treatment Using the Heli-FX Aortic Securement System Global Registry (ANCHOR) study. This prospective, multinational, real-world analysis of EndoAnchors comprised two groups of patients, those undergoing first-time EVAR (primary arm, 242) and those with proximal neck complications remote from the time of an initial endograft implantation (revision arm, 77). The primary arm was further subdivided into patients undergoing prophylactic EndoAnchor use for hostile proximal neck anatomy (178), with a type Ia endoleak evident during initial endograft deployment (60), and in conjunction with extender cuffs after unsatisfactory endograft deployment distally in the neck (four). The revision arm was subdivided into patients presenting with a type Ia endoleak alone (45), endograft migration alone (11), and migration with endoleak (21). Technical success was iter reported as satisfactory deployment of the desired number of EndoAnchors without fracture or loss of integrity. Procedural success was defined as technical success without type Ia endokak at completion arteriography. Core labontory analysis was performed on 249 baseline and 192 follow-up computed tomographic studies, 66 of which were available within the 1-year window.

Results: Technical and procedural success rates were highest in the prophylactically treated subset (17.2 of 17.8; 96.6%). Whereas the technical success of EndoAnchor deployment was also high in the other subsets, residual type Ia endolaaks were more frequent at completion angiography when the indication for EndoAnchor use was type Ia endoleaks both in the primary arm (17 of 60; 28%) and in the revision arm (9 of 45; 20%). During a median imaging follow-up of 7 months, 188 of 2021 patients (90.15%) remained free of type Ia endoleaks the revision patients treated for type Ia endoleaks in 110 of 114 cases (96.5%). The most challenging subset was revision patients treated for type Ia endoleaks in 110 of 114 cases (96.5%). The most challenging subset was revision patients treated for type Ia endoleaks in 120 of 26 of the cases (34%). Sac regression >5 mm in patients with 1-year imaging was observed in 26 of 66 patients (0.3%) and was highest in the primary prophylaxis subset (20 of 43; 47%). Complications in patients treated prophylaxis aubset (20 of 43; 47%). Complications in patients with hostile accession, for endograft migration. Whereas the most challenging patients on endoleaks, or, in conjunction with notic extension cuffs, for endograft migration. Whereas the most challenging patients are those who present with type Ia endoleak remote from initial EVAR. EndoAnchors are still effective in treating the majority of these cases. (J Vass Surg 2014;m:1-8.)

* Strong acute results in majority hostile neck anatomy


- * Zero type I endoleaks (0/178) at final angio
- *Favorable follow-up (mean 7-month)
 - * **Zero** re-interventions for type Ia endoleak or endograft migration (0/186)
 - * High early sac regression, 47% (20/43)

What We've Learned to Further Improve Outcomes

Lack of EndoAnchor penetration in aortic tissue may increase risk of developing/re-developing type I endoleaks

CoreLab assessment of etiology of residual type 1A after EndoAnchor placement (N =17)

Reason for persistent type 1a endoleak	Number of cases
Calcified Rim	5
Gap between graft and aortic wall	6
EndoAnchor deployed above graft fabric	3
EndoAnchor deployed in aneurysm sac	4
EndoAnchor not oriented perpendicular to graft wall	2



4 subjects had two reasons identified for persistent type 1a endoleak

Can It Fix Type I Endoleaks and Graft Migration: Can It Be Proven?

What we've learned...

- * EndoAnchors can be a powerful tool in fixing complications
 - * High success in treating type Ia endoleaks (>90%)
 - * Zero re-interventions for endograft migration in f/u

* Can enable viable treatment, especially when options are limited

- * High seal integrity despite high-risk neck anatomy
- * Maturing follow-up data are in-process

Site Name	Total Enrolle d	% of Total	Site Name	Total Enrolle d	% of Total
University of Alabama	43	8.9%	Vanderbilt University Medical Center	9	1.9%
St. Antonius Hospital	34	7.0%	Arizona Heart	2	0.4%
El Camino Hospital	16	3.3%	Beth Israel Deaconess Medical Center (BIDMC)	2	0.4%
Technical University Munich	11	2.3%	Hawaii Permanente Medical Group	11	2.3%
University Medical Center Utrecht	1	0.2%	Harbor - UCLA Medical Center	1	0.2%
Carolinas Health Care System	32	6.6%	Albany Medical Center	74	15.3%
William Beaumont Hospital	6	1.2%	Deutsches Herzzentrum Berlin	5	1.0%
Scott & White Medical Center	9	1.9%	Michigan Vascular Center	10	2.1%
Maasstad Medical Hospital Rotterdam	5	1.0%	Florida Hospital	25	5.2%
University of Siena	2	0.4%	Lexington Medical Center	30	6.2%
Malmo University Hospital	1	0.2%	Imperial College London	8	1.7%
Thorax Institute Hospital Clinic	4	0.8%	University of South Florida	3	0.6%
Park Hospital Leipzig	3	0.6%	Yale	7	1.4%
NYU School of Medicine	1	0.2%	Baptist Memphis	4	0.8%
Cleveland Clinic	6	1.2%	Johns Hopkins	6	1.2%
Central Arkansas Veterans Health System (CAVHS)	2	0.4%	HeartCare Peoria	3	0.6%
University of North Carolina	2	0.4%	Mount Sinai	3	0.6%
St. Bonifatius Hospital	4	0.8%	NorthShore University	1	0.2%
St. Franziskus-Hospital GmbH Munster	7	1.4%	University of Heidelberg	7	1.4%
Dartmouth-Hitchcock Medical Center	5	1.0%	LMU Munich	2	0.4%
Sentara Heart Hospital - Norfolk	15	3.1%	Klinikum Nürnberg	3	0.6%
Carolina Vascular-Mission Hospital	16	3.3%	Klinikum Ludwigsburg	1	0.2%
Southern Illnois University School of Medicine	1	0.2%	Rijnstate Hospital	7	1.4%
Washington University School of Medicine	9	1.9%	PinnacleHealth	3	0.6%
Baptist Hospital	4	0.8%	Loma Linda VA	4	0.8%
Montefiore Medical Center	3	0.6%	SUNY Stony Brook	5	1.0%
Duke University Medical Center	6	1.2%	Total	484	100%





